DURECT Corporation (DRRX)

Market Cap	26.85M
Revenue (ttm)	8.59M
Net Income (ttm)	-17.07M
Shares Out	31.04M
EPS (ttm)	-0.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,677
Open	0.885
Previous Close	0.920
Day's Range	0.850 - 0.885
52-Week Range	0.480 - 1.880
Beta	0.93
Analysts	Buy
Price Target	5.00 (+477.97%)
Earnings Date	Nov 13, 2024

About DRRX

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company’s lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osm...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 28, 2000
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: DRRX
• Website: https://www.durect.com

Financial Performance

In 2023, DURECT's revenue was $8.55 million, a decrease of -55.67% compared to the previous year's $19.28 million. Losses were -$27.62 million, -21.82% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for DRRX stock is "Buy." The 12-month stock price forecast is $5.0, which is an increase of 477.97% from the latest price.

Price Target

$5.0

(477.97% upside)

Analyst Consensus: Buy